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ABSTRACT
Aim: To find out the short-term outcome of ciliary ablation
with diode laser contact cyclophotocoagulation in
Nigerians with neovascular glaucoma.
Methods: The study is a retrospective, non-comparative,
interventional case series. Demographic data, ocular and
systemic history were obtained. Clinical examination
included visual acuity, intraocular pressure, number of
intraocular pressure-lowering medications and type of
treatment administered at the time of NVG diagnosis.
Treatment with diode laser cyclophotocoagulation was
instituted. Short-term outcomes were observed and
patients were followed-up for three months.
Results: The study included 3 eyes of 3 patients; all above 40
years, 1 female and 2 male. At the time of NVG
diagnosis, all three patients presented with severe ocular
pain, and had VA between PL and NPL. Intraocular
pressure on the average was 33mmHg at presentation,
and associated with corneal oedema. At 3 months after
initial diode laser photocoagulation (DLPC), the VA
remained the same in all patients. No patient required
repeat treatment. Pain reduction and lowering of the  
intraocular pressure were achieved at 3 months follow-
up post-DLPC without anti-glaucoma medication.
Conjunctival burns and chemosis were seen. All three
eyes had corneal oedema and spontaneous hyphema by
the 7  day; with subsequent severe corneal blood stain.th
Conclusions: Diode laser photocoagulation can be used as
an acceptable non-invasive surgical intervention for the
reduction of pain and lowering of intraocular pressure
in Nigerians with neovascular glaucoma. Most short-
term complications are uneventful. The presence of
hyphema with corneal oedema may enhance the
occurrence of corneal blood stain in black people. The
presence of corneal oedema may thus be a risk factor for
corneal blood staining.
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INTRODUCTION
Cyclophotocoagulation is a non-invasive surgical technique
suggested in the management of neovascular glaucoma, after
all modalities of medical and other surgical therapies have
failed.  Various lasers have been used for this procedure1,2,3
including, ruby, ND:YAG, argon, krypton and, more
recently, trans scleral cyclophotocoagulation with the diode
laser, which has been shown to be more effective with less
side effects than the others.  The diode laser, 810nm, has4,5
greater melanin absorption compared to other lasers. Of the
various cyclodestructive laser procedures, the semi
conductor diode system appears to posses the best
combination of effectiveness, portability, expense, safety and
ease of use.  5, 6
Three cases are described in this article to highlight the
short-term results of treatment with diode laser contact
cyclophotocoagulation (DLCP) in Nigerian patients with
neovascular glaucoma. To the best of the authors’
knowledge, there are no published short-term descriptions
of the reaction of Nigerians with NVG to DLPC. Various
theories have been described regarding the mechanism of
cyclophotocoagulation. These include decreased aqueous
production by destruction of ciliary blood vessels,
coagulative necrosis, and destruction of the ciliary
epithelium resulting in decreased aqueous production and
increased aqueous outflow. Whatever the mechanism, the
presence of ciliary body pigment is important in absorbing
laser energy.  Hyphema is commonly reported as one of the
complications of DLPC. This report is perhaps the first to
document corneal blood staining from the resultant
hyphema.
METHODS
Three patients diagnosed with  neovascular glaucoma were
retrospectively reviewed from their case notes. All the
patients had undergone a baseline systemic and ophthal-
mologic examinations, including visual acuity, IOP
measurement, slit lamp biomicroscopic examination at
presentation, before laser surgery, and at 1, 3, 6, and 12
months follow-up. Complications within the first three
months up to the 12  month were noted, and the numberth
and types of medication were recorded. 
Procedure for DLPC
DLPC was indicated for all three patients because their cases
were considered to be ocular emergencies; the patients were
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in pain and had sustained elevated intraocular pressure in
spite of anti-glaucoma medication. Two of the patients had
no perception of light and needed urgent pain relief. 
Success was defined as: final intraocular pressure
between 9 and 21 mmHg, relief of pain, no signs of  anterior
segment inflammation, discontinuation of carbonic
anhydrase inhibitor and no repeat procedure of DLPC.
Short-term follow-up was defined as from onset of DLPC to
the third month after surgery. 
All patients were treated as out patients. Peribulbar
anaesthesia was administered after cleaning with povidone
5%. Patients were supine. The probe was placed 2.0mm from
the limbus. The power settings were placed at a start of 1.2
watts and progressively increased until the pop sound was
heard. The power immediately below that at which the pop
sound was heard was the chosen as the power for treatment.
360E DLPC was performed on all eyes, however the number
of burns varied. The power setting was 1.6W in the first and
third cases and 1.7 W in the second case, for a duration of 1.5
seconds. The number of shots administered was 30 in the
second and third cases, while in the first it was 32 single
shots and not continuous.
All the patients had the same immediate post-operative
care. At the end of each procedure, an oral analgesic and anti
inflammatory agents were prescribed for three days duration
only. A topical antiglaucoma medication (Xalatan 0.001%)
was administered, and gradually tapered and discontinued
when the DLPC appeared to have taken effect. A topical
intensive steroid (Maxitrol) was utilized and gradually
tapered when inflammation appeared to have subsided.
Topical atropine 1% was also administered as well as a
prophylactic topical antibiotic (Ciloxan 0.3%) X4 daily.
RESULTS 
Case 1
A 72-year-old woman presented with intense pain in the
right eye of six months duration. She was a known
hypertensive patient of 20 years duration and diabetes
mellitus was confirmed 7 years earlier.   In addition, she was
diagnosed as having glaucoma about 8 months prior to the
time of presenting at clinic. Ophthalmic examination
revealed a visual acuity of NPL in the right eye and 6/24 in
the left. Intraocular pressure on presentation was 54mmhg
and 24mmhg in the right and left eye respectively. The right
eye revealed mild corneal oedema, a moderately shallow
anterior chamber, iris new vessel and intumescent  cataract.
In the left eye, a nuclear cataract and early posterior
subcapsular cataract were observed. Fundoscopy on the left
eye revealed glaucomatous optic neuropathy and  cup disc
ratio of 0.8. A diagnosis of right phacomorphic glaucoma,
and neovascular glaucoma was made. Angle details showed
a closed angle with a vascular membrane. The patient had
right uneventful endocapsular cataract extraction as an
emergency for phacogenic cataract. A week later, she had
contact DLPC as detailed in table 1.
Table 1. Clinical Characteristics
Character Case 1 Case 2 Case 3
Age 72 71 47
Sex F M M
System ic
disease
Diabetis Mellitus Hypertension None
System ic drugs Stopped 2 years prior to presentation Calcium 2 blocker Nil
Ocular drugs None None Abandoned medication & refused
surgery
Ocular RE LE RE LE RE LE
Pain Severe Nil Severe Nil Severe Nil
VA NPL 6/24 NPL 6/24 PL 3/60
IOP 54 24 37 18 42 28
Gonioscopy Closed angle, with
vascular membrane
Schaffer grd 3 Grade 3
(closed)NVG
Schaffer 3 Closed angle, new
vessels
Shaffer grd 3
Cornea Mild oedema Clear Mild Oedema Clear Moderate
Oedema
Iris Iris new vessel Normal iris new vessels Normal Iris new vessels
Lens Intumescent lens Posterior
Subcapsular
Nuclear sclerosis Nuclear sclerosis Poor details Clear
Vitreous haemorrhage clear Vitreous
haemorrhage
Clear clear Clear












Diagnosis Rt  Phacomorphic Glaucoma &
Neovascular Glaucoma
Lt Mild non Proliferative DR & OAG
NVG 2E? Branch Retinal Vein
Occlusion 
Rt NVG 2E ?CRVO
Lt Advanced or End stage Glaucoma
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Case 2
A 71-year-old man was referred to the eye clinic from the
hypertension clinic of the same institution on account of pain
and loss of vision in the left eye for 2 months. Visual acuity
was NPL in that eye. There was congestion, 5% hyphema 
and mild corneal oedema; however patient had iris new
vessels and moderate nuclear sclerosis. There was vitreous
haemorrhage with no red reflex or fundal details. Intraocular
pressure was 37 mmhg. The right eye had a visual acuity of
6/24; anterior segment was normal except for moderate
nuclear sclerosis. Fundoscopy revealed normal discs and
Grade 2 hypertensive retinopathy. Emergency treatment was
administered; with oral Diamox 500mg start and topical
Xalatan 0.001%. The patient had DLPC a week after
presentation. Response is shown in tables 1 to 4.
Case 3
A 47-year-old male glaucoma patient who had defaulted
from the eye clinic 12 years before, presented with nausea
and progressive pain in the right eye of 8 weeks duration.
Examination revealed visual acuity of PL in the right eye.
The eye was congested and there was corneal oedema. Twigs
of new vessels were seen on the iris. The anterior chamber
was deep. The lens was normal and clear, but there was a
poor red reflex due to vitreous haemorrhage. Pressure was
42mmhg in that eye and 28 in the left. Visual acuity in the
left eye was 3/60 with end stage glaucomatous atrophy and
an open angle. Emergency ocular treatment was
administered as in the previous cases. The patient had DLPC
a week after diagnosis. Again response is presented in the
tables.
Table 2. Ocular findings before and after diode laser contact cyclophotocoagulation
Outcom e m easure Case 1 Case 2 Case 3
VA NPL NPL PL
PAIN
Immediate preop moderate moderate Moderate
Day 1 Post op moderate moderate Moderate
1 week Post op Mild Mild Mild
1 month Post op none none None
3 month none none None
ANTERIOR UVEITIS
Immediate preop severe severe Severe
Day 1 Post op severe severe Severe
1 week Post op moderate moderate Moderate
1 month Post op mild mild Mild
3 month none none None
INTRAOCULAR PRESSURE
Immediate preop 32
NO Diamox      +        
Timoptol 0.5%
28
Diamox 250mg 6hrly +  
Xalatan 0.001%
39
Diamox 250mg 6hrly +  
Xalatan 0.001%
Day 1 Post op 31




Diamox 250mg 6hrly +
Xalatan 0.001%
32
Diamox 250mg 6hrly + 
Xalatan 0.001%
1 week Post op 28
NO Diamox +
Timoptol 0.5% + 
Xalatan 0.001%
24
Diamox 250mg 6hrly +  
Xalatan 0.001%
34
Diamox 250mg 6hrly + 
Xalatan 0.001%
1 month Post op 18
+  Xalatan 0.001%
12
+  Xalatan 0.001%
11
+  Xalatan 0.001%
3 month 12 10 9
HYPHEM A
Immediate preop Absent <5% Absent
Day 1 Post op Absent <5% Absent
1 week Post op 25% 40% 15%
1 month Post op No further view No further view No further view
3 month No further view No further view No further view
CORNEAL OEDEM A
Immediate preop mild Mild Moderate
Day 1 Post op mild Mild Severe
1 week Post op moderate Moderate Moderate
1 month Post op mild Mild Mild
3 month nil Nil Nil
CORNEAL BLOOD STAIN
Immediate preop Absent Absent Absent
Day 1 Post op Absent Absent Absent
1 week Post op Early corneal blood satin Early corneal blood stain Early corneal blood stain
1 month Post op Dense  corneal blood stain Dense corneal blood stain Dense corneal blood stain
3 month Same Same Same
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DISCUSSION
Neovascular glaucoma is not uncommon. It is a severe type
of secondary angle closure glaucoma caused by various
disorders and characterized by retinal ischaemia or ocular
inflammation. It is also common in poorly controlled
advanced chronic simple glaucoma . The visual prognosis
for NVG is usually poor.  Medical therapy is often not7
effective in controlling IOP when the outflow system has
been occluded.  Filtration is usually only successful when8,9
neovascularization has regressed after panretinal photo-
coagulation and a better outcome with the use of
antimetabolites. Tube shunt surgery has also been found to
be effective in reducing IOP. However, if these fail, a
cyclodestructive procedure may be necessary to reduce IOP.
The treatment of choice when the ocular media are clear is
panretinal photocoagulation in the first instance, and more
recently, intravitreal Avastin, irrespective of media clarity.3,8
In this series, none of the patients presented with a clear
ocular media, and all presented late, at least six weeks from
onset of pain. When a cloudy media prevents retinal laser
therapy, conservative and symptomatic treatment becomes
the option. DLPC has been identified as an efficient
treatment for neovascular glaucoma.  2, 5, 8, 10
Cyclophotocoagulation is indicated for: patients with
refractory glaucoma for  whom trabeculectomy or tube shunt
procedures have failed; patients with minimal useful vision
and elevated intraocular pressure; and patients who have no
visual potential and need pain relief.  The patients in this6
series fit into at least two of these categories. However, for
NVG in these patients, uncontrolled pain was the priority
indication for treatment. The use of diode laser
cyclophotocoagulation has been associated with variability
in laser parameters.  The higher the power, the more11
effective the therapy with DLPC.  The average is between11,12
1.6 and 3mW. The power used in this study was in the range
of 1.6-1.7W. The probability of success is increased
significantly with age, for patients older than 50 years.  Two13
of our patients were above 50 years, however, previous
ocular surgery decreased the success probability. This was
not the case in the diabetic who had cataract extraction prior
to DLPC.
Relief of pain occurred in all three patients without
systemic analgesia by the first week. This result is similar to
that of another study.13
Visual acuity remained the same in the only eye with
perception of light. Visual loss from perception of light to no
perception of light has been seen in other studies,9,10,14
however, this difference in results may be due to the fact that
our study population is small. 
DLPC may be an unpredictable procedure due to
variability in the surgeon’s delivery method, and variability
in pressure exerted over the sclera. Difference in scleral
pressure in patients may also contribute to this variability
but certain short-term complications of DLPC treatment may
be predictable. The use of DLPC in the treatment of NVG has
been shown to lower intraocular pressure and reduce ocular
pain regardless of its complications, as was seen in this
study. Furthermore, two out of the patients developed
persistently low intraocular pressure (less than 10mmhg),
after the third month.
Anterior segment inflammation, conjunctival oedema,
conjunctival congestion and conjunctival burns were noted
as early and short-term complications. This is similar to the
results in an earlier report.  Anterior segment and4
conjunctival inflammation subsided in all three cases by the
third month of follow-up. Conjunctival burns healed within
a week after surgery. Second or repeat treatment has been
carried out within six weeks of surgery, but this was not
necessary within the period of one to three months after the
initial treatment.1,8,14
Hyphema is a known complication of DLPC. This has
been documented to be a common side effect in patients with
NVG  when compared with some studies on POAG, in8,11
which it is said to be transient and not frequent. A
comparative study of NVG and POAG, however, did not
show any difference in the rate of hyphema.  The incidence10
rate of transient hyphema in the anterior chamber and of
transient exudate in the anterior chamber of patients with 
NVG were significantly higher,  with  an energy per pulse of
2.5W in 2 seconds  compared to 2.0W in 1.5 seconds.  This11
is higher than the energy pulse utilized in this report which
was between 1.6-1.7W.  The presence of ciliary body pigment
is important in absorbing laser energy. This contributes to
the need and effect of different energy pulse in people from
different racial backgrounds. The three patients discussed
were Nigerians.
 Corneal blood stain has not been documented in the use
of DLPC to treat NVG. Hyphema in the presence of corneal
endothelial compromise, and eventually corneal decompen-
sation, irrespective of the intraocular pressure, results in
corneal blood staining. In these three patients, corneal blood
staining was seen a week following hyphema in the presence
of corneal oedema; this, following a single treatment with
DLPC. This appears to be the most significant short-term
complication following DLPC treatment in this group of
patients. Anterior chamber paracentesis may be indicated in
such patients; however the patients in this review refused
surgery. Corneal blood staining was not an acceptable
cosmetic occurrence. While the pain was no longer a
problem to all three patients by the third month of review,
they all complained about the ‘dark colouring’ in the eye.
They found it undesirable but, in comparison to the pain,
were glad for the treatment. Patients should be warned that
corneal blood staining may occur  within the first week in
NVG following the use of DLPC in Nigerian patients. 
CONCLUSION
A short-term review of three cases of NVG in Nigerians
treated with DLPC showed that even though the procedure
is easy to perform, effective in lowering IOP, and is a safe
and less time-consuming method for pain relief and
lowering IOP, corneal blood staining may develop following
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hyphema and corneal decompensation. A prospective study
using a larger sample size for the treatment parameters may 
establish corneal oedema as a risk factor for corneal blood
staining. Furthermore, physicians should be cautious about
DLPC treatment of neovascular glaucoma associated with
corneal oedema. 
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